Ronald Evans

Ronald Evans

Directeur/Bestuurslid bij
The Salk Institute for Biological Studies
76 jaar
Health Technology
Commercial Services
Consumer Services

Profiel

Ronald M.
Evans
is the founder of Ligand Pharmaceuticals, Inc. (1987), Syndax Pharmaceuticals, Inc. (2005), Synchronicity Pharma, Inc. (2008), Mitobridge, Inc. (2013), and Metacrine, Inc. (2014).
He is also the founder of Xenopharm, Inc., X-Ceptor Therapeutics, Inc., XTuit Pharmaceuticals, Inc. Dr. Evans's current jobs include Director & Professor at The Salk Institute for Biological Studies, Director at American Association for Cancer Research, Member at National Academy of Sciences, Member at American Academy of Arts & Sciences, and Member at National Academy of Medicine (United States).
Dr. Evans received his doctorate degree from the University of California, Los Angeles in 1974 and his undergraduate degree from the same university in 1970.

Actieve functies van Ronald Evans

BedrijvenFunctieBegin
Directeur/Bestuurslid -
Corporate Officer/Principal 25-01-2010
Corporate Officer/Principal 25-01-2010
Corporate Officer/Principal 25-01-2010
Directeur/Bestuurslid -

Eerdere bekende functies van Ronald Evans

BedrijvenFunctieEinde
METACRINE, INC. Oprichter 23-03-2023
Oprichter -
Oprichter -
Oprichter -
░░░░░░░░░░ ░░░░ ░░░░░░░░░ -
Ervaring van Ronald Evans in detail bekijken

Opleiding van Ronald Evans

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

88

Eerstegraads connecties

14

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit14

Health Technology

Consumer Services

Health Technology

Commercial Services

Consumer Services

Commercial Services

Commercial Services

Commercial Services

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. Ronald Evans
-40 %: de beste tools exclusief voor abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU